Literature DB >> 5935708

In vivo metabolism of H3-medroxyprogesterone acetate in pregnant and nonpregnant women and in the fetus.

P K Besch, N Vorys, J C Ullery, R D Barry, D Couri.   

Abstract

Entities:  

Keywords:  Biology; Clinical Research; Comparative Studies; Contraception; Contraceptive Agents, Female--administraction and dosage; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--administraction and dosage; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--administraction and dosage; Contraceptive Agents--side effects; Contraceptive Methods--side effects; Embryo; Family Planning; Fetal Membranes; Fetus; Hormone Receptors; Medroxyprogesterone Acetate--administraction and dosage; Medroxyprogesterone Acetate--side effects; Membrane Proteins; Metabolic Effects; Oral Contraceptives--side effects; Physiology; Pregnancy--side effects; Reproduction; Research Methodology; Steroid Metabolic Effects; Studies

Mesh:

Substances:

Year:  1966        PMID: 5935708     DOI: 10.1016/0002-9378(66)90174-8

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


× No keyword cloud information.
  1 in total

1.  The pharmacokinetics of high-dose medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancer.

Authors:  H C Blossey; H H Bartsch; D Kanne; J Koebberling; G A Nagel
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.